AAAAAA
Results: 1-25/40
Authors:
ANDERSEN J
ANDERSSON W
ANDERSEN KW
DOMBERNOWSKY P
MOURIDSEN HT
ROSE C
KJAER M
GADEBERG C
HIRSCH FR
MOELLER A
Citation: J. Andersen et al., A RANDOMIZED PHASE-III TRIAL OF ADJUVANT ENDOCRINE THERAPY WITH TAMOXIFEN FOR ONE-YEAR (TAM1) VS TAMOXIFEN FOR 2 YEARS (TAM2) IN POSTMENOPAUSAL HIGH-RISK PATIENTS WITH ESTROGEN-RECEPTOR POSITIVE OR ESTROGEN-RECEPTOR UNKNOWN BREAST-CANCER - A DBCG STUDY, European journal of cancer, 34, 1998, pp. 168-168
Authors:
AAMDAL S
DOMBERNOWSKY P
WANDERS J
CAPRIATI A
LUND B
Citation: S. Aamdal et al., A PHASE-I STUDY OF THE NOVEL ANTRACYCLINE ANALOG MEN-10755 BMS-195615(NAA) IN PATIENTS (PTS) WITH A SOLID TUMOR - PRELIMINARY-RESULTS/, Annals of oncology, 9, 1998, pp. 656-656
Authors:
SIGSGAARD T
HERRSTEDT J
HANDBERG J
KJAER M
DOMBERNOWSKY P
Citation: T. Sigsgaard et al., RANDOMIZED, DOUBLE-BLIND, PARALLEL TRIAL OF THE ANTIEMETIC EFFICACY AND SAFETY OF ONDANSETRON (OND) PLUS METOPIMAZINE (MPZ) VERSUS OND PLUSMPZ PLUS PREDNISOLONE (PRED) DURING MULTIPLE CYCLES OF MODERATELY EMETOGENIC CHEMOTHERAPY (CT), Annals of oncology, 9, 1998, pp. 675-675
Authors:
SESSA C
WANDERS J
DOMBERNOWSKY P
NIELSEN D
MORANT R
DRINGS P
WISSEL P
HANAUSKE AR
Citation: C. Sessa et al., A PHASE-II STUDY WITH GI147211 (GW211) IN SMALL-CELL LUNG-CANCER (SCLC), Annals of oncology, 9, 1998, pp. 255-255
Authors:
DOMBERNOWSKY P
SMITH I
FALKSON G
LEONARD R
PANASCI L
BELLMUNT J
BEZWODA W
GARDIN G
GUDGEON A
MORGAN M
FORNASIERO A
HOFFMANN W
MICHEL J
HATSCHEK T
TJABBES T
CHAUDRI HA
HORNBERGER U
TRUNET PF
Citation: P. Dombernowsky et al., LETROZOLE, A NEW ORAL AROMATASE INHIBITOR FOR ADVANCED BREAST-CANCER - DOUBLE-BLIND RANDOMIZED TRIAL SHOWING A DOSE-EFFECT AND IMPROVED EFFICACY AND TOLERABILITY COMPARED WITH MEGESTROL-ACETATE, Journal of clinical oncology, 16(2), 1998, pp. 453-461
Authors:
RYBERG M
NIELSEN D
SKOVSGAARD T
HANSEN J
JENSEN BV
DOMBERNOWSKY P
Citation: M. Ryberg et al., EPIRUBICIN CARDIOTOXICITY - AN ANALYSIS OF 469 PATIENTS WITH METASTATIC BREAST-CANCER, Journal of clinical oncology, 16(11), 1998, pp. 3502-3508
Authors:
LASSEN UN
HIRSCH FR
OSTERLIND K
BERGMAN B
DOMBERNOWSKY P
Citation: Un. Lassen et al., OUTCOME OF COMBINATION CHEMOTHERAPY IN EXTENSIVE-STAGE SMALL-CELL LUNG-CANCER - ANY TREATMENT RELATED PROGRESS, Lung cancer, 20(3), 1998, pp. 151-160
Authors:
DOMBERNOWSKY P
GIACCONE G
SANDLER A
SCHWARTSMANN G
Citation: P. Dombernowsky et al., GEMCITABINE AND PACLITAXEL COMBINATIONS IN NONSMALL CELL LUNG-CANCER, Seminars in oncology, 25(4), 1998, pp. 44-50
Authors:
JORGENSEN L
BRUNNER N
SPANGTHOMSEN M
JAMES MR
CLARKE R
DOMBERNOWSKY P
SVENSTRUP B
Citation: L. Jorgensen et al., STEROID-METABOLISM IN THE HORMONE-DEPENDENT MCF-7 HUMAN BREAST-CARCINOMA CELL-LINE AND ITS 2 HORMONE-RESISTANT SUBPOPULATIONS MCF-7 LCC1 AND MCF-7/LCC2/, Journal of steroid biochemistry and molecular biology, 63(4-6), 1997, pp. 275-281
Authors:
ANDERSSON M
MADSEN EL
OVERGAARD M
DOMBERNOWSKY P
MOURIDSEN HT
Citation: M. Andersson et al., CAF VS CMF BOTH WITH TAMOXIFEN IN POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER - A RANDOMIZED STUDY WITH MORE THAN 10 YEARS FOLLOW-UP FROM THE DANISH BREAST-CANCER COOPERATIVE GROUP, European journal of cancer, 33, 1997, pp. 648-648
Authors:
STENBYGAARD LE
SORENSEN JB
LARSEN H
DOMBERNOWSKY P
Citation: Le. Stenbygaard et al., PRETREATMENT PREDICTORS OF METASTATIC POTENTIAL VERIFIED AT AUTOPSY IN PATIENTS (PTS) WITH INOPERABLE NONSMALL CELL LUNG-CANCER (NSCLC), European journal of cancer, 33, 1997, pp. 1051-1051
Authors:
SOLETORMOS G
FOGH JM
SEHESTEDHANSEN B
SPANGTHOMSEN M
SCHIOLER V
DOMBERNOWSKY P
SKOVSGAARD T
Citation: G. Soletormos et al., CARCINOEMBRYONIC ANTIGEN IN MONITORING THE GROWTH OF HUMAN COLON ADENOCARCINOMA TUMOR-CELLS SK-CO-1 AND HT-29 IN-VITRO AND IN NUDE-MICE, European journal of cancer, 33(1), 1997, pp. 108-114
Authors:
ARDIZZONI A
HANSEN H
DOMBERNOWSKY P
GAMUCCI T
KAPLAN S
POSTMUS P
GIACCONE G
SCHAEFER B
WANDERS J
VERWEIJ J
Citation: A. Ardizzoni et al., TOPOTECAN, A NEW ACTIVE-DRUG IN THE 2ND-LINE TREATMENT OF SMALL-CELL LUNG-CANCER - A PHASE-II STUDY IN PATIENTS WITH REFRACTORY AND SENSITIVE DISEASE, Journal of clinical oncology, 15(5), 1997, pp. 2090-2096
Authors:
HERRSTEDT J
SIGSGAARD T
HANDBERG J
SCHOUSBOE BMB
HANSEN M
DOMBERNOWSKY P
Citation: J. Herrstedt et al., RANDOMIZED, DOUBLE-BLIND COMPARISON OF ONDANSETRON VERSUS ONDANSETRONPLUS METOPIMAZINE AS ANTIEMETIC PROPHYLAXIS DURING PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH CANCER, Journal of clinical oncology, 15(4), 1997, pp. 1690-1696
Authors:
DOMBERNOWSKY P
BOESGAARD M
ANDERSEN E
JENSEN PV
Citation: P. Dombernowsky et al., DOXORUBICIN PLUS PACLITAXEL IN ADVANCED BREAST-CANCER, Seminars in oncology, 24(5), 1997, pp. 15-18
Authors:
SORENSEN JB
WEDERVANG K
DOMBERNOWSKY P
Citation: Jb. Sorensen et al., PRELIMINARY-RESULTS OF A PHASE-II STUDY OF PACLITAXEL AND CISPLATIN IN PATIENTS WITH NONSMALL CELL LUNG-CANCER, Seminars in oncology, 24(4), 1997, pp. 18-20
Authors:
GEHL J
BOESGAARD M
PAASKE T
JENSEN BV
DOMBERNOWSKY P
Citation: J. Gehl et al., COMBINED DOXORUBICIN AND PACLITAXEL IN ADVANCED BREAST-CANCER - EFFECTIVE AND CARDIOTOXIC, Annals of oncology, 7(7), 1996, pp. 687-693
Authors:
LASSEN U
KRISTJANSEN PEG
OSTERLIND K
BERGMAN B
SIGSGAARD TC
HIRSCH FR
HANSEN M
DOMBERNOWSKY P
HANSEN HH
Citation: U. Lassen et al., SUPERIORITY OF CISPLATIN OR CARBOPLATIN IN COMBINATION WITH TENIPOSIDE AND VINCRISTINE IN THE INDUCTION CHEMOTHERAPY OF SMALL-CELL LUNG-CANCER - A RANDOMIZED TRIAL WITH 5 YEARS FOLLOW-UP, Annals of oncology, 7(4), 1996, pp. 365-371
Authors:
GEHL J
BOESGAARD M
PAASKE T
JENSEN BV
DOMBERNOWSKY P
Citation: J. Gehl et al., PACLITAXEL AND DOXORUBICIN IN METASTATIC BREAST-CANCER, Seminars in oncology, 23(6), 1996, pp. 35-38
DOXORUBICIN AND PACLITAXEL, A HIGHLY-ACTIVE COMBINATION IN THE TREATMENT OF METASTATIC BREAST-CANCER
Authors:
DOMBERNOWSKY P
GEHL J
BOESGAARD M
PAASKE T
JENSEN BV
Citation: P. Dombernowsky et al., DOXORUBICIN AND PACLITAXEL, A HIGHLY-ACTIVE COMBINATION IN THE TREATMENT OF METASTATIC BREAST-CANCER, Seminars in oncology, 23(5), 1996, pp. 23-27
PACLITAXEL AND DOXORUBICIN, A HIGHLY-ACTIVE COMBINATION IN THE TREATMENT OF METASTATIC BREAST-CANCER
Authors:
DOMBERNOWSKY P
GEHL J
BOESGAARD M
JENSEN TP
JENSEN BV
Citation: P. Dombernowsky et al., PACLITAXEL AND DOXORUBICIN, A HIGHLY-ACTIVE COMBINATION IN THE TREATMENT OF METASTATIC BREAST-CANCER, Seminars in oncology, 23(1), 1996, pp. 13-18
Authors:
SOLETORMOS G
NIELSEN D
SCHIOLER V
SKOVSGAARD T
DOMBERNOWSKY P
Citation: G. Soletormos et al., TUMOR-MARKERS CANCER ANTIGEN-15.3, CARCINOEMBRYONIC ANTIGEN, AND TISSUE POLYPEPTIDE ANTIGEN FOR MONITORING METASTATIC BREAST-CANCER DURING FIRST-LINE CHEMOTHERAPY AND FOLLOW-UP, Clinical chemistry, 42(4), 1996, pp. 564-575
Authors:
ARDIZZONI A
HANSEN HH
DOMBERNOWSKY P
KAPLAN S
POSTMUS PE
GAMUCCI T
SCHAEFER B
WANDERS J
VERWEIJ J
Citation: A. Ardizzoni et al., PHASE-II STUDY OF TOPOTECAN IN REFRACTORY AND SENSITIVE SMALL-CELL LUNG-CANCER (SCLC), European journal of cancer, 31A, 1995, pp. 84-84
Authors:
LARSEN H
SORENSEN JB
NIELSEN AL
DOMBERNOWSKY P
HANSEN HH
Citation: H. Larsen et al., EVALUATION OF THE OPTIMAL DURATION OF CHEMOTHERAPY IN PHASE-II TRIALSFOR INOPERABLE NON-SMALL-CELL LUNG-CANCER (NSCLC), Annals of oncology, 6(10), 1995, pp. 993-997
Authors:
LASSEN U
OSTERLIND K
HANSEN M
DOMBERNOWSKY P
BERGMAN B
HANSEN HH
Citation: U. Lassen et al., LONG-TERM SURVIVAL IN SMALL-CELL LUNG-CANCER - POSTTREATMENT CHARACTERISTICS IN PATIENTS SURVIVING 5 TO 18- AN ANALYSIS OF 1,714 CONSECUTIVE PATIENTS( YEARS ), Journal of clinical oncology, 13(5), 1995, pp. 1215-1220